Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four Phase 2 clinical trials.

Learn more

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four Phase 2 clinical trials.

Learn more

Developing Breakthrough Therapies for Rare Inflammatory Diseases

Resunab is a first in class, synthetic oral endocannabinoid-mimetic drug that resolves chronic inflammation and halts fibrotic processes. It is currently being evaluated in four Phase 2 clinical trials.

Learn more
About

About

Corbus Pharmaceuticals is a clinical stage biopharmaceutical company focusing on rare, life-threatening, chronic inflammatory diseases. Learn More
Technology

Technology

Our technology revolves around the development and commercialization of novel therapeutics to treat life threatening ("orphan") inflammatory-fibrotic diseases.

Learn More
Indications

Indications

Corbus Pharmaceuticals is dedicated to developing therapeutics that help to better the lives of patients with rare chronic inflammatory conditions.

Learn More

Pipeline

Corbus Pharmaceuticals is developing Resunab for the treatment of chronic ("orphan") inflammatory diseases in which inflammation leads to chronic fibrosis.

View Details
Preclinical Phase 1 Phase 2 Phase 3
Cystic Fibrosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Systemic Sclerosis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Dermatomyositis
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Systemic Lupus Erythematosus
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started

Sign up for Email Alerts

Receive breaking news first!

Sign up today

Investor Presentation